Biogen Inc. (BIIB) research, news, and more from GeoInvesting

Company description

Wed, 05 Mar 2008 05:00:00 GMT

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.

Comments & Business Outlook

Tue, 21 Jul 2009 04:00:00 GMT

Biogen has updated its previously issued guidance.

FULL YEAR 2009 Guidance Ending December ^a

	Full Year 2009 Guidance	Full Year 2008 Reported	Period Change
GAAP EPS	above $2.75	$2.65	3.8%
Non-GAAP EPS ^b	above $3.85	$3.66	5.2%

Source: See Release, July 16, 2009.

^a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement.

^b Non-GAAP EPS figures generally exclude certain non-operating gains and losses as well as certain non-cash items. Non-GAAP information should not be viewed in isolation or as a substitute for reported, or GAAP information . For a more complete explanation of the company's definition of non-GAAP please refer to its financial press releases. The GeoTeam® non-GAAP figures may, from time to time, differ from company supplied figures.

Comments & Business Outlook

Thu, 25 Jun 2009 04:00:00 GMT

Biogen Idec confirmed full year 2009 financial guidance outlined in February this year, consistent with achieving the Company’s 2010 financial goals

Comments & Business Outlook

Sat, 14 Feb 2009 05:00:00 GMT

Guidance Report:

Full Year Fiscal 2009 Guidance Ending December

	2009 Guidance	2008 Reported	Period Change
GAAP EPS	Above $2.80	$2.65	5.7%
*Non-GAAP EPS	Above $4.00	$3.66	9.3%

*Non-GAAP EPS Figures exclude non-operating gains and losses.

" WE believe it is important to share these Non-GAAP financial measures with shareholders as they better represent the ongoing economics of the business, reflect how we manage the business internally and set operational goals, and form the basis of our management incentive programs. Non-GAAP net income and diluted EPS should not be viewed in isolation or as a substitute for reported, or GAAP, net income and diluted EPS."

Source: Business Wire (February 6, 2009)